Polar Asset Management Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Polar Asset Management Partners’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,300	Closed	-$792K	–	822
2025 Q2	$792K	Buy	+25,300	New	+$825K	0.01%	389
2022 Q3	–	Sell	-124,000	Closed	-$3.77M	–	1487
2022 Q2	$3.77M	Buy	124,000 +45,700	+58%	+$1.38M	0.04%	573
2022 Q1	$2.39M	Hold	78,300	–	–	0.03%	601
2021 Q4	$2.45M	Buy	+78,300	New	+$2.34M	0.03%	570

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Polar Asset Management Partners's XENE Position: Q3 2025 in Review

Polar Asset Management Partners sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 25,300 shares — an estimated $792K sold.

Polar Asset Management Partners first reported a position in XENE in Q4 2021 and held it in 4 quarters. The position peaked at $3.77M in Q2 2022. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

Polar Asset Management Partners reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Polar Asset Management Partners sold 25,300 Xenon Pharmaceuticals shares in Q3 2025, an estimated $792K.
Polar Asset Management Partners first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 4 quarters.
Polar Asset Management Partners's Xenon Pharmaceuticals position peaked at $3.77M in Q2 2022.
219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Polar Asset Management Partners's 13F filing for Q3 2025, filed 14 Nov 2025.